...Xiaofan Hu; Hong Ren; Jing Xu; Chenni Gao; Yifan Wu; Yan Ouyang; Li Lin; Xiao Li; Na Liu; Weiming Wang; Jingyuan Xie; Nan Chen Introduction: Previous studies have shown that rituximab (RTX) and cyclic oral corticosteroid-cyclophosphamide (CTX) regimens have similar effects on primary membranous...

... is an independent protective factor for proliferative LN patients achieving complete remission with cyclophosphamide as induction therapy (OR = 0.978; 95% CI 0.961–0.996; p < 0.05). Conclusion: High plasma ADMA levels in combination with eGFR and complement C3 may be useful to diagnose diffuse proliferative LN...

... respond better to some modes of treatment [e.g. cyclophosphamide (CYC) or rituximab] and may be less frequently refractory to treatment compared to black patients with LN. Although these differences may be largely genetically driven, socioeconomic factors (poverty, education, insurance, access to health...

... predispositions that might partly contribute to the clinical variations observed. Corticosteroids combined with either cyclophosphamide (CYC) or mycophenolic acid (MPA) is the current standard-of-care induction regimen for severe LN irrespective of race or ethnicity. However, the preference for MPA or CYC...